AI-driven drug discovery, precision medicine, and sustainable manufacturing can redefine the pharma…
Ramandeep Singh, Vice President, Life Sciences and Healthcare, India, Clarivate, discusses the latest innovative R&D,…
Author
Balancing MAGA and MIGA
While the PILLS Act, aims for “strategically incentivising reshoring of essential medicines” to the US, India Pharma Inc cannot do…
India is rising from a CDMO perspective when it comes to biologics
Bill Coyle, principal, ZS, discusses India's growing role in biologics from a CDMO perspective and how AI is shaping pharma.…
Trumping the Budget blues?
Perhaps the uncertainty of the Union Budget pales before the changes that US President Trump will make as he gets down to business…
India’s biopharma industry needs to become a little bit more ambitious
In a free wheeling conversation with Viveka Roychowdhury, Dr Dhananjay Patankar, biopharma consultant, explains why Indian…
Will Epygen’s biosimilars bets pay off?
Debayan Ghosh, founder, Epygen Group, has ambitious plans to snag a slice of the booming $70 billion global biosimilar pie. In a…
2025: A year of stricter rules, course corrections?
Will 2025 see a more vigilant government when it comes to violations by pharma companies, be it GMP slip ups or the Uniform Code…
Eco-conscious packaging: A strategic opportunity
Larger pharma companies are applying sustainable practices and eco-conscious materials to packaging and labelling, leading to…
ACG covers every facet of the pharma process, all under one roof and seamlessly interconnected
ACG Inspection’s Life Sciences Cloud will be making its India debut at the CPhI India- PMec India 2024 show. Udit Singh, CEO, ACG…
We, at OmniActive, invest over 10 per cent of the total outlay into R&D
Sanjaya Mariwala, Executive Chairman and MD, OmniActive Health Technologies shares insights into the company’s significant…